Allan Miller

Dr Allan Miller qualified in medicine at St Bartholomew's Hospital Medical School, London in 1961.
In 1965 Dr Miller was admitted to the Royal College of Physicians.
After spending 8 years in general practice he was appointed as a medical adviser to international pharmaceutical company, Hoffman La Roche.
Dr Miller oversaw the clinical research program for both Isotretinoin and Etretinate and its successor Acitretin.
Each of these products was registered worldwide and granted marketing authorization.
At Hoffman La Roche Dr Miller held the positions of Head of Clinical Cardiovascular Research Worldwide, Head of Dermatological Research Worldwide and Head of all Clinical Research UK.
During his time with Hoffman La Roche, over 9 separate products were successfully registered.
In 1984, Dr Miller joined a U.S.
privately owned pharmaceutical group, Purdue Pharma, Mundipharma in Europe and Napp Pharma as Medical Director.
Dr Miller established the clinical programs for controlled release tablets, which led to the establishment of the controlled release morphine products.
This new palliative process pioneered by Dr Miller's team some 20 years ago has now used throughout the world.
Dr Miller spent 14 years as Medical Director for Napp Pharmaceuticals Ltd and 4 years as European Medical Research Director of the Purdue Pharma, Mundipharma, Napp group based in Cambridge, England.
Dr Miller is also a Member of the British Medical Association and a Fellow of the Royal Society of Medicine.